Please assess the completion status of the following clinical trial:

Trial Title: Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* GHDA subjects as defined in the Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II~* Fertile females must agree to use appropriate contraceptive methods and have a negative pregnancy test at inclusion~* GH replacement therapy for more than 3 months~* Body Mass Index (BMI, kg/m2) of 22.0 to 35.0 kg/m2, both inclusive~Exclusion Criteria:~* Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods~* Malignant disease~* Proliferative retinopathy judged by retina-photo within the last year - only with concomitant diabetes~* Heart insufficiency, NYHA class greater than 2~* Subjects with diabetes with an HbA1C above 8.0%~* Diabetic receiving insulin treatment~* Stable pituitary replacement therapy for less than 3 months~* Impaired liver function~* Impaired kidney function

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: EXPERIMENTAL): None
- C (Type: EXPERIMENTAL): None
- D (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).